IFNA1 and acquired polycythemia vera: The use of recombinant IFN-α (rIFN-α-2b) or PEG-IFN-α-2a in the treatment of PV can result in a significant reduction in the phlebotomy rate and is effective in inducing hematologic remission and in some cases reducing expression of JAK2V617F [33].